Factors associated with patient’s compliance to anti­­­hypertensive treatment

Main Article Content

T. G. Slascheva
G. D. Radchenko
Yu. M. Sirenko
I. M. Martsovenko


The aim – to evaluate factors related to the compliance and its changes during antihypertensive treatment.
Material and methods. We included 10  158 hypertensive patients, treated by 531 general practice physicians. Physicians administered antihypertensive therapy based on domestic generic drugs (bisoprolol, enalapril, fixed combination enalapril and hydrochlorthiazide, amlodipine) during 3 months. Every patient had four visits to the physician’s office with evaluation of the office blood pressure and heart rate, ECG patterns, compliance (by questionnaire).
Results. It was shown that 43.2 % hypertensive patients had low (< 50 % taking prescribed drugs) compliance baseline. Factors associated with poor compliance were older age, presence of coronary heart disease, myocardial infarction, stroke or heart failure, lifestyle (higher body mass index, smoking, alcohol abuse, low physical activity, low consumption of fresh fruits and vegetables, high salt consumption), low education and absence of work (or being retired). The level of blood pressure was higher in patients with baseline low compliance at all 4 visits. The target blood pressure was not achieved in 33.5 % patients with high compliance, in 39,9 % with baseline moderate compliance (P<0.001 vs high) and in 47.6 % (P<0.001 vs high and 0.005 with moderate) with low baseline compliance. In 61.7 % patients we noted improving of the compliance. Independent factors associated with final visit compliance were age (β=–0.024, Р=0.018), baseline compliance (β=0.61, P<0.001), level of systolic (β=–0.05, P<0.001) and diastolic (β=–0.04, P<0.001) blood pressure at the end of the study, presence of adverse reactions (β=–0.04, P<0,001), alcohol abuse (β=–0.03, P=0.004), physical activity (β=0.034, P=0.002), consumption of fresh vegetables and fruits (β=0.026, P=0.02).
Conclusion. Administration of fixed combination of enalapril and hydrochlorthiazide and higher doses of bisoprolol and amlodipine, as well as printed recommendations for lifestyle modification were related to better compliance at the end of the study.

Article Details


arterial hypertension, compliance


Сіренко Ю.М., Радченко Г.Д., Марцовенко І.М. від імені учасників дослідження. Результати тримісячного спостереження за лікуванням пацієнтів з артеріальною гіпертензією лікарями загальної практики в Україні (Програма «Можливо­­­сті ефективного контролю артеріального тиску за допомогою вітчизняних ліків») // Артеріальна гіпертензія.– 2009.– № 4.– С. 3–14.

ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertension.– 2013.– Vol. 31.– P. 1281–1357.

Akpaffiong M., Lawson M. Noncompliance to antihypertensive Drug therapy: a risk factor in Stroke-associated death in Minority populations // J. Hypertens.– 2004.– Vol. 17.– P. 68.

Andrade S., Gurwitz J., Field T. et al. Hypertension management: the care gap between clinical guildelines and clinical practice // Amer. J. Manag. Care.– 2004.– Vol. 10.– P. 481–486.

Azizi M., Menard J., Peyrard S. et al. Assessment of patient’s and physician’s compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the noninsulin-dependent diabetes, hypertension, microalbuminuria, proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study // Diabetes Care.– 2006.– Vol. 29.– P. 1331–1335.

Babazono A., Miyazaki M., Imatoh T. et al. Effects of the increase in co-payments from 20 to 30 percent on the compliance rate of patients with hypertension or diabetes mellitus in the employed health insurance system // Int. J. Technol. Assess. Health Care.– 2005.– Vol. 21.– P. 228–233.

Bandura A. Social foundations of thought and action.– New Jersey: Prentice Hall, 1986.– 101 p.

Bloom B. Daily regimen and compliance with treatment // Brit. Med. J.– 2001.– Vol. 323.– P. 647.

Buabeng K., Matowe L., Plange-Rhule J. Unaffordable drug prices: the major cause of non-compliance with hypertension medication in Ghana // J. Pharm. Sci.– 2004.– Vol. 7.– P. 350–352.

Burnie M. Compliance in hypertension // EDTNA ERCA J.– 2005.– Vol. 31.– P. 152–155.

Chen K., Glass D., Chiou C et al. Adverse Effects and Reason for switch reported by patients on antihypertensive therapy // Am. J. Hypertens.– 2004.– Vol. 17.– P. 102.

Cochrane G.M., Horne R., Chanez P. Compliance in asthma // Respir. Med.– 1999.– Vol. 93.– P. 763–769.

Colhoun H.M, Doug W., Poulter N.R. Blood pressure screening, management and control in England: results from the health survey for England // J. Hypertens.– 1998.– Vol. 16.– P. 747.–752.

Contreras E., Guillen V., Martinez J.J. et al. Analysis of studies published on hypertension treatment non-compliance in Spain between 1984 and 2005 // Aten. Primaria.– 2006.– Vol. 38.– P. 325–332.

Contreras E., von Wichmann M., de la Figuera et al. Com­­pliance with hypertension therapy in Spain, according to the views of family doctors. Complex project // Intern. Emerg. Med.– 2006.– Vol. 1.– P. 204–208.

Di Matteo M.R. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research // Med. Care.– 2004.– Vol. 42.– P. 200–209.

Dydensborg C.I., Krabbe T. Compliance of hypertension patients estimated by means of website tool // Ugeskr. Laeger.– 2007.– Vol. 169.– P. 4347–4350.

Elliot W. The economic impact of hypertension // J. Clin. Hypertens.– 2003.– Vol. 5 (Suppl. 2).– P. 3–13.

Enlund H., Jokisalo E., Wallenius S. et al. Patient-percieved problems, compliance and the outcome of hypertension treatment // Pharm. World Sci.– 2001.– Vol. 23.– P. 60–64.

Flack J., Casciano R., Casciano J. et al. Cardiovascular disease costs associated with uncontrolled hypertension // Manag Care Interface.– 2002.– Vol. 15.– P. 28–36.

Fodor G., Kotrec M., Bacskai K. et al. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central European study // J. Hypertens.– 2005.– Vol. 23.– P. 1261–1266.

Gascon J., Sanchez-Ortunob M., Llorc B. et al. for the Treatment Compliance in Hypertension Study Group. Why hypertensive patients do not comply with the treatment Results from a qualitative study // Family Practice.– 2004.– Vol. 21.– P. 125–130.

Gerbino P., Bramley T., Nightengale B., et al. Effect of medication compliance with antihypertensive therapy on blood pressure control // Am. J. Hypertens.– 2004.– Vol. 17.– P. 222A.

Girerd X., Fourcade J., Brillet G. et al. The compliance evaluation test: a validated tool for detection of nonadherence among hypertensive treated patients // J. Hypertens.– 2001.– Vol. 19.– P. 74S.

Girerd X., Hanon O., Anagnostopoulos K. et al. Evaluation de l’observance du traitement antihypertenseur par un questionnaire: mise au point et utilization dans un service specialize // Presse Med.– 2001.– Vol. 30.– P. 1044–1048.

Halpern M., Khan Z., Schmier J. et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data // Hypertens.– 2006.– Vol. 47.– P. 1039–1048.

Hodgson T., Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities // Med Care.– 2001.– Vol. 39.– P. 599–615.

Horne R. Compliance, adherence and concordance. Implications for Asthma treatment // Chest.– 2006.– Vol. 130.– P. 65S–72S.

Jeong B.S., Gang H.G., Gwak M.Y. et al. Effects of biophysical index, knowledge, and self management compliance of patients with primary hypertension by a self management compliance promotion program // Taehan. Kanho Hakhoe Chi.– 2006.– Vol. 36.– P. 551–560.

Kerse N., Buetow S., Mainous A. et al. Physician-Patient relationship and medication compliance: a primary care investigation // Ann. Fam. Med.– 2004.– Vol. 2.– P. 455–461.

Kiiskinen U., Vartianinen E., Puska P. et al. Long-term cost and life-expectancy consequences of hypertension // J. Hypertens.– 1998.– Vol. 16.– P. 1103–1112.

Krousel-Wood M., Hyre A., Muntner P., Morisky D. Methods to improve medication adherence in patients with hypertension: current status and future directions // Curr. Opin. Cardiol.– 2005.– Vol. 20.– P. 96–300.

Lagi A., Rossi A., Passaleva M. et al. Compliance with therapy in hypertensive patients // Intern. Emerg. Med.– 2006 .– Vol. 1.– P. 204–208.

Lawers C., Vander Hoorn S., Law M. et al. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Volume 1. Geneva, Switzerland: World Health Organization.– 2004.– P. 281–389.

Maetzel A., Li L., Pencharz J. et al. The economic burden associated with osteoarthrosis, reumatoid arthritis and hypertension: a comparative study // Ann. Reum. Dis.– 2004.– Vol. 63.– P. 395–401.

Mancia G., Bombelli M., Corrao G. et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis // Hypertens.– 2007.– Vol. 49.– P. 40–47.

Mar J., Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? // J. Hypertens.– 2001.– Vol. 19.– P. 149–155.

Mendoza P., Munoz P., Merino E., Barriga O.R. Determinant factors of therapeutic compliance in elderly hypertensive patients // Rev. Med. Chil.– 2006.– Vol. 134.– P. 65–71.

Mino-Leon D., Reyes-Morales H., Galvan-Plata M.E. et al. Drug treatment of hypertension: compliance and adverse reactions in a cohort of hypertensive patients in a primary care setting // Rev. Invest. Clin.– 2007.– Vol. 59.– P. 8–14.

Weir M., Maibach E., Bakris G. et al. Implications of the health and lifestyle and medication analysis for improving hypertension control // Arch. Intern. Med.– 200.– Vol. 160.– P. 481–490.

Most read articles by the same author(s)

1 2 > >>